SEARCH

SEARCH BY CITATION

References

  • 1
    Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol2009; 27: 484857.
  • 2
    Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol2003; 1: 6738.
  • 3
    Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie2012; 32: 11525.
  • 4
    Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res2009; 148: 3141.
  • 5
    Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res2012; 129(Suppl. 1): S1326.
  • 6
    Garnier D, Magnus N, D’Asti E, Hashemi M, Meehan B, Milsom C, Rak J. Genetic pathways linking hemostasis and cancer. Thromb Res2012; 129(Suppl. 1): S229.
  • 7
    Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation2003; 107: I1721.
  • 8
    Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol.2005; 6: 40110.
  • 9
    Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol2009; 27: 491926.
  • 10
    Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood2009; 113: 187591.
  • 11
    Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol2009; 27: 483947.
  • 12
    Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia2012; 26: 56371.
  • 13
    Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. Vasc Med2011; 16: 11930.
  • 14
    Di Nisio M, Ferrante N, Feragalli B, De Tursi M, Iacobelli S, Cuccurullo F, Porreca E. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res2011; 127: 3823.
  • 15
    Arboix A. [Cerebrovascular disease in the cancer patient]. Rev Neurol2000; 31: 12502.
  • 16
    Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia2008; 22: 20208.
  • 17
    Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res2011; 17: 585866.
  • 18
    Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, Schleinitz N, Valla D, Galicier L, Bengrine-Lefevre L, Gorin NC, Coppo P. Cancer awareness in atypical thrombotic microangiopathies. Oncologist2009; 14: 76979.
  • 19
    Kansu E. Thrombosis in stem cell transplantation. Hematology2012; 17(Suppl. 1): S15962.
  • 20
    Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant2010; 16: 15768.
  • 21
    Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia2003; 17: 163642.
  • 22
    Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer1986; 57: 18469.
  • 23
    Rosovsky R, Lee AY. Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy?Hematology Am Soc Hematol Educ Program2010; 2010: 1502.
  • 24
    Piccioli A, Lensing AW, Prins MH, Falanga A, Scannapieco GL, Ieran M, Cigolini M, Ambrosio GB, Monreal M, Girolami A, Prandoni P. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost2004; 2: 8849.
  • 25
    van Doormaal FF, Terpstra W, van Der Griend R, Prins MH, Nijziel MR, van de Ree MA, Buller HR, Dutilh JC, ten Cate-Hoek A, van den Heiligenberg SM, van der Meer J, Otten JM. Is extensive screening for cancer in idiopathic venous thromboembolism warranted?J Thromb Haemost2011; 9: 7984.
  • 26
    Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res2012; 129(Suppl. 1): S668.
  • 27
    Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood2011; 117: 677785.
  • 28
    Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost2001; 86: 82833.
  • 29
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med2000; 160: 80915.
  • 30
    Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol2006; 24: 48490.
  • 31
    Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002; 100: 34848.
  • 32
    Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg2007; 106: 6018.
  • 33
    Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol2009; 22: 923.
  • 34
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer2007; 110: 233946.
  • 35
    Falanga A, Marchetti M. Anticancer treatment and thrombosis. Thromb Res2012; 129: 3539.
  • 36
    Lechner D, Weltermann A. Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?Semin Thromb Hemost2008; 34: 199203.
  • 37
    Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol2009; 22: 4960.
  • 38
    Pickering W, Gray E, Goodall AH, Ran S, Thorpe PE, Barrowcliffe TW. Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. J Thromb Haemost2004; 2: 45967.
  • 39
    Fernandes RS, Kirszberg C, Rumjanek VM, Monteiro RQ. On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost2006; 4: 154652.
  • 40
    Nadir Y, Brenner B, Gingis-Velitski S, Levy-Adam F, Ilan N, Zcharia E, Nadir E, Vlodavsky I. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost2008; 99: 13341.
  • 41
    Kozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SG. Application of cancer procoagulant as an early detection tumor marker. Cancer1994; 74: 136776.
  • 42
    Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G. Procoagulant factors in patients with cancer. Hematology2007; 12: 5559.
  • 43
    Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med2004; 53: 21030.
  • 44
    van Aalderen MC, Trappenburg MC, van Schilfgaarde M, Molenaar PJ, ten Cate H, Terpstra WE, Leyte A. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost2011; 9: 2236.
  • 45
    Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, Leebeek FW. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost2011; 105: 1420.
  • 46
    Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica2009; 94: 9118.
  • 47
    Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer2003; 39: 18491.
  • 48
    Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, Ruan C. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res2011; 35: 87984.
  • 49
    Garnier D, Magnus N, D’Asti E, Hashemi M, Meehan B, Milsom C, Rak J. Genetic pathways linking hemostasis and cancer. Thromb Res2012; 129(Suppl. 1): S229.
  • 50
    Regina S, Valentin JB, Lachot S, Lemarie E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem2009; 55: 183442.
  • 51
    Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res2002; 62: 696672.
  • 52
    Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res2012; 129(Suppl. 1): S307.
  • 53
    Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood2005; 105: 17885.
  • 54
    Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest2003; 124: 58S68S.
  • 55
    Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res2007; 120: S712.
  • 56
    Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA1997; 94: 6638.
  • 57
    Liu Y, Kalen A, Risto O, Wahlstrom O. Time- and pH-dependent release of PDGF and TGF-beta from platelets in vitro. Platelets2003; 14: 2337.
  • 58
    Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol2007; 27: 145662.
  • 59
    Kocaturk B, Versteeg HH. Tissue factor isoforms in cancer and coagulation: may the best isoform win. Thromb Res2012; 129(Suppl. 1): S6975.
  • 60
    Rak J. Microparticles in cancer. Semin Thromb Hemost2010; 36: 888906.
  • 61
    Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K, Sulowska Z. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol2008; 68: 32836.
  • 62
    Falanga A, Vignoli A, Diani E, Marchetti M. Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Relat Outcome Meas2011; 2: 17588.
  • 63
    Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol2009; 27: 490211.
  • 64
    Noble S. Low-molecular-weight heparin and survival in lung cancer. Thromb Res2012; 129(Suppl. 1): S1148.
  • 65
    van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol2011; 29: 20716.
  • 66
    Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, Kauschat-Bruning D, Bramlage P, Dorken B, Oettle H. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer2008; 8: 361.
  • 67
    Maraveyas A, Waters J, Roy R, Propper D, Fyfe D, Lofts F, Gardiner E, Sgouros J, Wedgwood K. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metatastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Suppl2009; 7: 362.
  • 68
    Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer2009; 9: 355.
  • 69
    Spek CA, Arruda VR. The protein C pathway in cancer metastasis. Thromb Res2012; 129(Suppl. 1): S804.
  • 70
    Horowitz NA. Mechanisms coupling thrombomodulin to tumor dissemination. Thromb Res2012; 129(Suppl. 1): S11921.
  • 71
    Falanga A, Marchetti M. Venous thromboembolism in hematologic malignancies. In: Khorana AA, Francis CW, eds. Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment. New York, NY: Informa Healthcare, 2008: 13149.
  • 72
    Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med2004; 350: 11424.
  • 73
    Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res2010; 125(Suppl. 2): S12833.
  • 74
    Mandala M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol2006; 59: 194204.
  • 75
    Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quere I, Levesque H, Debourdeau P. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol2010; 73: 3146.
  • 76
    Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol2011; 22(Suppl. 6): vi8592.
  • 77
    Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res2010; 125(Suppl. 2): S1207.
  • 78
    Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med2002; 346: 97580.
  • 79
    Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visona A. Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1). Thromb Res2012; 129: e1716.
  • 80
    Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer2012; 48: 128392.
  • 81
    Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol2009; 10: 9439.
  • 82
    Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med2012; 366: 6019.
  • 83
    Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, et al. Venous thromboembolic disease. J Natl Compr Canc Netw2011; 9: 71477.
  • 84
    Falanga A, Rickles FR. Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program2007; 16571.
  • 85
    Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol2005; 23: 40639.
  • 86
    Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, Gussoni G, Barbui T, Mannucci PM. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol2005; 129: 8117.
  • 87
    Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost2011; 9: 65363.
  • 88
    Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol2011; 29: 98693.
  • 89
    Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood2012; 119: 9339; quiz 1093.
  • 90
    Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol2007; 25: 5490505.
  • 91
    Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol2010; 21(Suppl. 5): v2746.
  • 92
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008; 22: 41423.
  • 93
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008; 111: 49027.
  • 94
    Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood2010; 116: 537782.
  • 95
    Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res2009; 15: 683040.
  • 96
    Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med2002; 162: 172935.
  • 97
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003; 349: 14653.
  • 98
    Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost2006; 12: 38996.
  • 99
    Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med2006; 119: 106272.
  • 100
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008; 133: 454S545S.
  • 101
    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol2000; 18: 307883.
  • 102
    Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost2009; 7: 7605.
  • 103
    Panova-Noeva M, Falanga A. Treatment of thromboembolism in cancer patients. Expert Opin Pharmacother2010; 11: 204958.
  • 104
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med2009; 361: 234252.
  • 105
    Buller H. EINSTEIN. European Society of Cardiology. Sep 2010 meeting 2010.
  • 106
    Verso M, Agnelli G. New and old anticoagulants in cancer. Thromb Res2012; 129(Suppl. 1): S1015.
  • 107
    Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis2011; 3: e2011068.
  • 108
    Falanga A, Marchetti M, Barbui T. All-trans-retinoic acid and bleeding/thrombosis. Pathophysiol Haemost Thromb2003; 33(Suppl. 1): 1921.
  • 109
    de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood2008; 111: 3395402.